Researcher
Jo A Van Ginderachter
- Keywords (Vrije Universiteit Brussel):Applied biological sciences, biotechnology, General and logistic services
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Adaptive immunology, Bacteriology
- Disciplines (Vrije Universiteit Brussel):Applied immunology
Affiliations
- Brussels Center for Immunology (Research group)
Member
From1 Jan 2023 → Today - R&D centraal (Administrative office)
Member
From3 Jun 2024 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Jan 2024 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2019 → 31 Dec 2023 - Department of Bio-engineering Sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2019 - Van Ginderachter Lab
Responsible
From1 Jan 2017 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2012 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2010 → 20 Oct 2022 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 1999 → 30 Sep 2014 - FORMER_Cellular and Molecular Immunology (Research group)
Responsible
From1 Oct 1995 → 1 Jan 2023
Projects
1 - 10 of 36
- 3D-CELLMAP: Unveiling complex cellular interactions in tissues through 3D super-resolution protein multiplex imagingFrom1 May 2024 → TodayFunding: FWO Medium Size Research Infrastructure
- Therapeutic targeting of tumor-associated macrophages with anti-CD163 Nanobody-drug conjugates as novel cancer therapyFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Engineering the tumor immune microenvironment in colorectal peritoneal metastases by locoregional delivery of toll like receptor agonistsFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- The role of lipid-associated macrophages in the tumor microenvironment and their evaluation as therapeutic targetFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Blocking the immunoregulatory family members D-dopachrome tautomerase (D-DT) and Macrophage Migration Inhibitory Factor (MIF) to improve immunotherapy of cancerFrom1 Nov 2022 → TodayFunding: FWO fellowships
- SRP-Onderzoekszwaartepunt: ITAREG: Molecular Imaging and TArgeting of immunoREGulatory cells in Inflammatory diseases and cancerFrom1 Nov 2022 → TodayFunding: BOF - projects
- IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Oct 2022 → 31 Mar 2024Funding: IOF - technology validation in real environment
- SBO Project : LipoMacs: functional Lipidomics to unlock Macrophage-mediated therapyFrom1 Oct 2022 → TodayFunding: FWO Strategic Basic Research (SBO)
- CASA PETIt: CAmera for Small Animal PET-ImagingFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Tricking tumor immunosuppression: RNA epigenetics as novel target to improve cancer immunotherapyFrom1 Jan 2022 → TodayFunding: FWO EOS
Publications
1 - 10 of 149
- The role of RNA modifications in disease-associated macrophages(2024)
Authors: Camille Huart, Mayuk Saibal Gupta, Jo Agnes Van Ginderachter
- Specific Imaging of CD8+ T-Cell Dynamics with a Nanobody Radiotracer against Human CD8β(2024)
Authors: Timo W M De Groof, Yoline Lauwers, Tessa De Pauw, Mohit Saxena, Cécile Vincke, Jolien Van Craenenbroeck, Catherine Chapon, Roger Le Grand, Geert Raes, Thibaut Naninck, et al.
- Q586B2 is a crucial virulence factor during the early stages of Trypanosoma brucei infection that is conserved amongst trypanosomatids(2024)
Authors: Benoit Stijlemans, Patrick De Baetselier, Inge Van Molle, Laurence Lecordier, Erika Hendrickx, Ema Romão, Cécile Vincke, Wendy Baetens, Steve Schoonooghe, Gholamreza Hassanzadeh Ghassabeh, et al.
- Peroxiredoxin-1 is an H2O2 safe-guard antioxidant and signalling enzyme in M1 macrophages(2023)
Authors: Daria Ezeriņa, Trung Nghia Vo, Ting Luo, Yvon Elkrim, Anna Escoda Suarez, Gaëtan Herinckx, Didier Vertommen, Damya Laoui, Jo Agnes Van Ginderachter, Joris Messens
- Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α(2023)
Authors: Yana Dekempeneer, Sam Massa, Francis Santens, Laurent Navarro, Marion Berdal, Melissa Miranda Lucero, Ana Rita Pombo Antunes, Tony Lahoutte, Jo Agnes Van Ginderachter, Nick Devoogdt, et al.
Pages: 1941-1948 - Lipocalin-2: A Nurturer of Tumor Progression and a Novel Candidate for Targeted Cancer Therapy(2023)
Authors: Maida Živalj, Jo Agnes Van Ginderachter, Benoit Stijlemans
- Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)(2023)
Authors: Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, et al.
Pages: 1378-1384 - A few good reasons to use nanobodies for cancer treatment(2023)
Authors: Neema Ahishakiye Jumapili, Maida Zivalj, Romina Mora Barthelmess, G Raes, Timo W M De Groof, Nick Devoogdt, Benoit Stijlemans, Cécile Vincke, Jo Agnes Van Ginderachter
Pages: 1-8 - Current status and future expectations of nanobodies in oncology trials(2023)
Authors: Tessa De Pauw, Lynn De Mey, Jens Debacker, Geert Raes, Jo Agnes Van Ginderachter, Timo W M De Groof, Nick Devoogdt
Pages: 705-721 - Ontogeny, functions and reprogramming of Kupffer cells upon infectious disease(2023)
Authors: Mohamed Amer Musrati, Patrick De Baetselier, Kiavash Movahedi, Jo A Van Ginderachter
Patents
1 - 6 of 6
- Non-blocking human ccr8 binders (Inventor)
- Human ccr8 binders (Inventor)
- A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer (Inventor)
- Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages (Inventor)
- Tumor-associated dendritic cell preparations and uses thereof (Inventor)
- Murine cross-reactive human ccr8 binders (Inventor)